Page 47 - brain-eBook

Team Project Name 4.The movement disorders produced by MSA mice

Building a new hope for treating multiple system and MSA patients can be effectively improved by
RS-D7/RS-D7pro drug in our studies.
atrophy using transdisciplinary approach: from 5.Both intravenous injection and oral gavage of
NMDA receptor modulators, preclinical models, to RS-D7 showed therapeutic effect in MSA/ataxia
clinical trials mouse models.
Research Project 6.RS-D7 has multiple indications and it can be
Multiple System Atrophy (MSA) is a rare, adult- used as a drug with multiple benefits.
onset, fatal, and progressive neurodegenerative 7.RS-D7 has obtained a number of domestic and
disorder. The onset of MSA generally occurs foreign intellectual property, and is exclusively
between the 5th to 6th decade of life, and the authorized to the Yoda Pharmaceutical Inc. It has
mean survival time from the onset of symptoms passed the U.S. FDA orphan drug qualification
is 8 to 10 years (average 9 years). However, the (ODD) review in July, 2022. And the first phase
etiology and underlying neuropathophysiological of clinical trials of new drugs was launched in
mechanisms of MSA remain much unclear and October, 2024.
whose treatment is not addressed adequately by Key Words
current available therapy. MSA is still an unmet
medical need. Previous studies suggest that the multiple system atrophy (MSA), unmet medical
α-synuclein aggregation and NMDA receptor need, neurodegenerative disorder, transdisciplinary
hypofunction play vital roles in the pathogenesis approach, NMDA receptor modulator, preclinical
of MSA. D-amino acid oxidase (DAO) inhibitor is models, clinical trial, neural network chip,
now of great interest for the treatment of MSA. Our exosomes, transcranial electrical neurostimulation,
inter-institutional research team has developed and cognitive functions, digital biomarkers, D-amino
studied RS-D7, a novel DAO inhibitor, since 2014. acid oxidase (DAO) inhibitor, new drug
Findings from our team and labs indicate that RS- development, RS-D7/YA-101
D7 is a powerful DAO inhibitor which facilitate Global Cooperation
NMDA receptor functions and alleviate observed New drug testing, mechanism of action (MOA),
MSA-related motor deficits in animal models exosome analysis, RNAseq, bio-chip development
and a proof-concept clinical trial. These results etc.
support the involvement of NMDA receptors in the
pathogenesis of MSA and therapeutic potential of Project Web Page
RS-D7 in the treatment of MSA. The innovation ● Laboratory of Integrated Neuroscience and
and technical advancement of RS-D7 includes the Ethology
following: ● English introductory website for our clinical study
1.RS-D7, a NCE and a novel DAO inhibitor, has a and experiments
great potential to be a first-in-class drug for the
treatment of MSA.
2.RS-D7 has a very good safety profile and is
suitable for long-term use.
3.RS-D7 demonstrated the inhibition of DAO and
inflammation in our preclinical models.

46 47